FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETY
Functional gastrointestinal disorders are currently being considered as the most common pathology of the gastrointestinal tract. Symptoms that may be related to the gastroduodenal region, represent one of the major subgroups among functional gastrointestinal disorders, in which the functional dyspep...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1801 |
| _version_ | 1797841833444769792 |
|---|---|
| author | D. I. Trukhan |
| author_facet | D. I. Trukhan |
| author_sort | D. I. Trukhan |
| collection | DOAJ |
| description | Functional gastrointestinal disorders are currently being considered as the most common pathology of the gastrointestinal tract. Symptoms that may be related to the gastroduodenal region, represent one of the major subgroups among functional gastrointestinal disorders, in which the functional dyspepsia rightly maintains leading positions syndrome. Pathogenetic factors of functional dyspepsia and other functional gastrointestinal disorders, which can be regarded as proven at the moment, are the dysmotility of the gastrointestinal tract, which determines the feasibility of using in the basic treatment of these diseases medications that affect motor function of the gastrointestinal tract and preventing anastaltic contractions of the smooth muscles, which are combined into a group of prokinetic. With comorbidity positions, clinical efficacy and drug safety is a priority itopride hydrochloride prokinetics in treatment of functional dyspepsia and other related functional gastrointestinal disorders. |
| first_indexed | 2024-04-09T16:37:35Z |
| format | Article |
| id | doaj.art-589d0f54ddaa4ff6a45477a98bf44f17 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:37:35Z |
| publishDate | 2017-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-589d0f54ddaa4ff6a45477a98bf44f172023-04-23T06:56:50ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-12-010510811510.21518/2079-701X-2017-5-108-1151779FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETYD. I. Trukhan0Federal State Educational Institution of Higher Education «Omsk state medical university» Ministry for Public Health of the Russian FederationFunctional gastrointestinal disorders are currently being considered as the most common pathology of the gastrointestinal tract. Symptoms that may be related to the gastroduodenal region, represent one of the major subgroups among functional gastrointestinal disorders, in which the functional dyspepsia rightly maintains leading positions syndrome. Pathogenetic factors of functional dyspepsia and other functional gastrointestinal disorders, which can be regarded as proven at the moment, are the dysmotility of the gastrointestinal tract, which determines the feasibility of using in the basic treatment of these diseases medications that affect motor function of the gastrointestinal tract and preventing anastaltic contractions of the smooth muscles, which are combined into a group of prokinetic. With comorbidity positions, clinical efficacy and drug safety is a priority itopride hydrochloride prokinetics in treatment of functional dyspepsia and other related functional gastrointestinal disorders.https://www.med-sovet.pro/jour/article/view/1801functional gastrointestinal disordersfunctional dyspepsiagastroesophageal reflux diseaseprokineticsitopride hydrochlorideitopra ® |
| spellingShingle | D. I. Trukhan FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETY Медицинский совет functional gastrointestinal disorders functional dyspepsia gastroesophageal reflux disease prokinetics itopride hydrochloride itopra ® |
| title | FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETY |
| title_full | FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETY |
| title_fullStr | FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETY |
| title_full_unstemmed | FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETY |
| title_short | FUNCTIONAL GASTROINTESTINAL DISORDERS: SELECT FROM THE POINT PROKINETIC COMORBIDITY, CLINICAL EFFICACY AND DRUG SAFETY |
| title_sort | functional gastrointestinal disorders select from the point prokinetic comorbidity clinical efficacy and drug safety |
| topic | functional gastrointestinal disorders functional dyspepsia gastroesophageal reflux disease prokinetics itopride hydrochloride itopra ® |
| url | https://www.med-sovet.pro/jour/article/view/1801 |
| work_keys_str_mv | AT ditrukhan functionalgastrointestinaldisordersselectfromthepointprokineticcomorbidityclinicalefficacyanddrugsafety |